Zacks Research Forecasts Weaker Earnings for DENTSPLY SIRONA

Key Points

• Zacks Research lowered its Q3 2026 EPS forecast for DENTSPLY SIRONA to $0.31 from $0.37. Its full-year 2026 estimate is $1.50 per share, compared with the company’s guidance range of $1.40–$1.50.
• Analyst sentiment remains cautious, with a consensus rating of “Hold” and an average price target of $13.54. The stock recently opened at $11.04, below its 50-day and 200-day moving averages.
• DENTSPLY SIRONA’s latest quarterly results exceeded expectations, reporting $0.52 EPS and $898 million in revenue, although revenue declined 4.1% year over year and the company posted a negative net margin.

DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report) - Stock analysts at Zacks Research cut their Q3 2026 EPS estimates for DENTSPLY SIRONA in a research note issued to investors on Thursday, August 27th. Zacks Research analyst Team now forecasts that the medical instruments supplier will post earnings of $0.31 per share for the quarter, down from their prior forecast of $0.37. The consensus estimate for DENTSPLY SIRONA's current full-year earnings is $1.41 per share. Zacks Research also issued estimates for DENTSPLY SIRONA's Q4 2026 earnings at $0.40 EPS, FY2026 earnings at $1.50 EPS, Q2 2027 earnings at $0.38 EPS, Q3 2027 earnings at $0.41 EPS, Q4 2027 earnings at $0.39 EPS, FY2027 earnings at $1.50 EPS, Q1 2028 earnings at $0.35 EPS, Q2 2028 earnings at $0.41 EPS and FY2028 earnings at $1.64 EPS.

A number of other analysts also recently issued reports on XRAY. Barrington Research set a $15.00 price objective on DENTSPLY SIRONA in a research report on Monday, August 10th. Piper Sandler upped their target price on shares of DENTSPLY SIRONA from $13.00 to $14.00 and gave the company a "neutral" rating in a research report on Wednesday, July 29th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of DENTSPLY SIRONA in a research note on Monday, August 3rd. BMO Capital Markets reiterated a "market perform" rating and set a $13.00 price target on shares of DENTSPLY SIRONA in a research report on Friday, August 7th. Finally, Mizuho dropped their price target on shares of DENTSPLY SIRONA from $16.00 to $14.00 and set a "neutral" rating for the company in a research report on Wednesday, May 6th. Three equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of "Hold" and an average target price of $13.54.

DENTSPLY SIRONA Price Performance

NASDAQ:XRAY opened at $11.04 on Friday. DENTSPLY SIRONA has a 52 week low of $9.40 and a 52 week high of $14.86. The stock's fifty day moving average is $12.08 and its two-hundred day moving average is $11.75. The company has a market capitalization of $2.20 billion, a P/E ratio of -4.01, a P/E/G ratio of 1.38 and a beta of 0.85. The company has a quick ratio of 1.07, a current ratio of 1.63 and a debt-to-equity ratio of 1.48.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.35 by $0.17. The business had revenue of $898.00 million during the quarter, compared to the consensus estimate of $889.93 million. DENTSPLY SIRONA had a negative net margin of 14.99% and a positive return on equity of 20.84%. The business's revenue was down 4.1% compared to the same quarter last year. During the same quarter last year, the firm earned $0.52 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS.

Institutional Investors Weigh In On DENTSPLY SIRONA

Several large investors have recently added to or reduced their stakes in the business. Eurizon Capital SGR S.p.A. purchased a new position in DENTSPLY SIRONA in the 4th quarter valued at approximately $26,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of DENTSPLY SIRONA in the first quarter worth $26,000. Caitong International Asset Management Co. Ltd increased its position in shares of DENTSPLY SIRONA by 337.9% during the third quarter. Caitong International Asset Management Co. Ltd now owns 2,750 shares of the medical instruments supplier's stock worth $35,000 after acquiring an additional 2,122 shares during the period. Nykredit A S acquired a new stake in shares of DENTSPLY SIRONA in the second quarter valued at $38,000. Finally, Farther Finance Advisors LLC raised its stake in shares of DENTSPLY SIRONA by 119.1% in the fourth quarter. Farther Finance Advisors LLC now owns 3,773 shares of the medical instruments supplier's stock valued at $43,000 after acquiring an additional 2,051 shares in the last quarter. 95.70% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Brian T. Gladden acquired 9,985 shares of the business's stock in a transaction that occurred on Monday, June 15th. The shares were purchased at an average price of $10.02 per share, for a total transaction of $100,049.70. Following the acquisition, the director owned 61,849 shares of the company's stock, valued at $619,726.98. This represents a 19.25% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Brian P. Mckeon acquired 10,000 shares of the business's stock in a transaction that occurred on Friday, June 12th. The stock was purchased at an average price of $10.12 per share, for a total transaction of $101,200.00. Following the acquisition, the director directly owned 10,000 shares in the company, valued at approximately $101,200. This trade represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders bought 35,160 shares of company stock valued at $351,179. 0.46% of the stock is currently owned by corporate insiders.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc NASDAQ: XRAY is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company's product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source